Related to EC Follows FDA and Approves Lilly’s Erectile Dysfunction Drug for BPH

• Biogen Idec’s Fampyra for MS Fails to Win CHMP Support in Europe
  
• Novartis Wins Positive Recommendation for Its MS Drug from CHMP
  
• EMA Road Map Aims to Stimulate Drug Development for Unmet Medical Needs and Rare and Neglected Diseases
  
• AmoyDx Gains CE Mark for EGFR, KRAS, and BRAF Tests
  
• Pfizer Wins EMA Approval to Market Dupuytren Contracture Therapy
  
• Baxter’s Vero Cell Seasonal Flu Vaccine Preflucel Approved in 13 European Countries
  
• EC Approves InterMune’s Esbriet for the Treatment of Idiopathic Pulmonary Fibrosis
  
• EC Approves BMS and AstraZeneca’s Type 2 Diabetes Therapy for Renally Impaired Patients
  
• EC Approves Janssen’s Extended-Release Injectable Schizophrenia Drug Xeplion
  
• ExonHit Gets EC Clearance for Alzheimer Disease In Vitro Diagnostic
  
• FDA Stalls Approval of Lilly’s Alzheimer Disease Imaging Agent
  
• EU Sanctions Novartis’ Multiple Sclerosis Drug Gilenya
  
• Amgen to Appeal EMA’s Negative Opinion on Vectibix Combination with Chemotherapy
  
• FDA Approves Type 2 Diabetes Drug from Boehringer Ingelheim and Lilly
  
• Luminex’ xTAG Gastrointestinal Pathogen Panel Gains CE Mark
  
• Roche’s Multivirus Blood-Screening Assay Achieves CE Mark
  
• Novartis’ Lucentis Approved in Europe for Treating Macular Edema Secondary to RVO
  
• EU Approves Biogen Idec’s Avonex Intramuscular Autoinjector Product for MS
  
• CHMP Says AMT’s Lipoprotein Lipase Deficiency Candidate Can’t Yet Be Approved
  
• EC Approves New Avastin Combination for Breast Cancer